Analyst Price Targets — PHAT
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 27, 2026 8:55 am | Jenna Davidner | Barclays | $18.00 | $10.58 | TheFly | Phathom Pharmaceuticals upgraded to Overweight from Equal Weight at Barclays |
| February 26, 2026 5:51 pm | Annabel Samimy | Stifel Nicolaus | $28.00 | $13.62 | StreetInsider | Stifel Reiterates Buy Rating on Phathom Pharmaceuticals (PHAT) |
| December 11, 2025 9:10 pm | Martin Auster | Raymond James | $28.00 | $14.56 | TheFly | Phathom Pharmaceuticals initiated with a Strong Buy at Raymond James |
| December 8, 2025 9:27 pm | Jenna Davidner | Barclays | $16.00 | $14.90 | TheFly | Phathom Pharmaceuticals initiated with an Equal Weight at Barclays |
| October 31, 2025 1:26 pm | Chase Knickerbocker | Craig-Hallum | $22.00 | $13.76 | TheFly | Phathom Pharmaceuticals price target raised to $22 from $17 at Craig-Hallum |
| October 31, 2025 10:10 am | — | H.C. Wainwright | $26.00 | $13.31 | TheFly | Phathom Pharmaceuticals price target raised to $26 from $20 at H.C. Wainwright |
| October 30, 2025 4:03 pm | Yatin Suneja | Guggenheim | $20.00 | $13.31 | StreetInsider | Phathom Pharmaceuticals (PHAT) PT Raised to $20 at Guggenheim |
| March 7, 2025 2:16 pm | — | Guggenheim | $18.00 | $5.06 | TheFly | Phathom Pharmaceuticals price target lowered to $18 from $28 at Guggenheim |
| August 8, 2024 4:17 pm | Paul Choi | Goldman Sachs | $12.00 | $11.75 | StreetInsider | Phathom Pharmaceuticals (PHAT) PT Raised to $12 at Goldman Sachs |
| July 19, 2024 10:02 am | Matthew Caufield | H.C. Wainwright | $28.00 | $10.95 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Phathom Pharmaceuticals (PHAT) |
Latest News for PHAT
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the nine analysts that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, six have given a buy recommendation and one has
FLORHAM PARK, N.J., April 06, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, announced today that members of its management team are scheduled to participate in the following upcoming investor conferences in April: Raymond James 2026 Biotech Innovation Symposium in New…
Barclays analyst Jenna Davidner upgraded Phathom Pharmaceuticals (NASDAQ:PHAT) to Overweight from Equal Weight on Friday, raising her price target to $18 from $16.
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the nine ratings firms that are currently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, five have issued a buy rating and one
Phathom Pharmaceuticals, Inc. (PHAT) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for PHAT.
U.S. House Trading
No House trades found for PHAT.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.